Module

Clinical Management of a Patient Who Develops Additional Resistance Mutations When Maintained on a Failing Antiretroviral Regimen

Source: Rethinking the Role of NNRTIs: Clinical Strategies for Optimizing Outcomes With Next-Generation Agents

Clinical Management of a Patient Who Develops Additional Resistance Mutations When Maintained on a Failing Antiretroviral Regimen


Faculty:

  • Joseph J. Eron, Jr., MD

CME CREDIT INFORMATION

Release Date: 03/03/08

Expiration Date: 03/02/09


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Registered Nurses: 0.6 Nursing CE credit

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss how emergent NNRTI mutations following virologic rebound may impact subsequent therapy decisions
  • Describe the known predictors of etravirine virologic response
  • Summarize data from clinical trials suggesting that achieving HIV-1 RNA < 50 copies/mL is possible in highly treatment–experienced patients
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.